Changes in Registrant’s Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm On August 21, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Inhibikase Therapeutics, Inc. (the “Company”) approved the dismissal of CohnReznick LLP (“CohnReznick”) as the Company’s independent registered public accounting firm, effective immediately. The audit reports of CohnReznick on the Company’s consolidated financial statements for the fiscal year…

Unregistered Sales of Equity Securities. On July 29, 2026, we entered into an exchange agreement with RA Capital Healthcare Fund, L.P., or RA Capital, pursuant to which RA Capital exchanged 18,030,000 shares of our common stock, par value $0.001 per share, or common stock, for a pre-funded warrant to acquire 18,030,000 shares of our common stock. The pre-funded warrant has an exercise price of $0.001 per underlying share of common stock, are immediately exercisable and have no expiration date…

Annual board election held in a routine manner.

Results of Operations and Financial Condition. On May 12, 2026, Inhibikase Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Se…

Results of Operations and Financial Condition. On March 26, 2026, Inhibikase Therapeutics, Inc. announced its financial results for the year ended December 31, 2025 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of…

Other Events. On December 19, 2025, Inhibikase Therapeutics, Inc. (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) a prospectus supplement (the “Prospectus Supplement”), dated December 19, 2025, with respect to the Company’s existing “at the market offering” program (the “ATM Program”). Pursuant to the Prospectus Supplement, the Company may offer and sell shares of its common stock having an aggregate offering price of up to $185,000,000, from time to time, throug…

Other Events. Effective November 20, 2025, the Company and the holders of all of the outstanding Series A-1 Warrants to Purchase Common Stock or Pre-Funded Warrants (each, a “Series A-1 Warrant”) and outstanding Series B-1 Warrants to Purchase Common Stock or Pre-Funded Warrants (each, a “Series B-1 Warrant”) issued on October 21, 2024, amended the terms of the Series A-1 Warrants (the “Amendment to Series A-1 Warrant”) and the Series B-1 Warrants (the “Amendment to Series B-1 Warrant”) to re…

Entry into a Material Definitive Agreement. On November 20, 2025, Inhibikase Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, BofA Securities, Inc. and Cantor Fitzgerald & Co., as representatives of the several underwriters listed on Schedule A thereto (collectively, the “Underwriters”), relating to an underwritten public offering (the “Offering”) of (i) 46,091,739 shares (the “Shares”) of the Company’s common stock,…

Effective November 20, 2025, the Company terminated the sales agreement prospectus (the “ATM Prospectus”) filed with the Company’s registration statement on Form S-3 (File No. 333- 288213) and related to the shares of our common stock issuable pursuant to the Open Market Sale Agreement SM , dated June 20, 2025 (the “Sales Agreement”), by and between the Company and Jefferies LLC. As of the date hereof, the Company had not made any sales pursuant to the ATM Prospectus. Further, the Company wil…

Results of Operations and Financial Condition. On November 14, 2025, Inhibikase Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2025 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purpo…

of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference…

Results of Operations and Financial Condition. On May 14, 2025, Inhibikase Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2025 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Se…

Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer — Garth Lees-Rolfe: Mr. Lees-Rolfe resigned and was succeeded by David McIntyre.

Results of Operations and Financial Condition. On March 27, 2025, Inhibikase Therapeutics, Inc. announced its financial results for the year ended December 31, 2024 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of…

Entry into a Material Definitive Agreement. On February 21, 2025 (the “Closing Date”), Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Project IKT Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”), CorHepta Pharmaceuticals, Inc., a Delaware corporation (“CorHepta”), and Preston S. Klassen, solely in his capacity as sellers’ repre…

by reference. The Consideration Shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and the Company offered the Consideration Shares in reliance upon the exemption from registration contained in Section 4(a)(2) of the Securities Act.

President and Head of Research and Development — Chris Cabell: Dr. Chris Cabell was appointed as President and Head of Research and Development in connection with a merger.

CEO — Milton H. Werner, Ph.D.: Dr. Milton H. Werner resigned as CEO and was succeeded by Mark Iwicki.

Other Events. On January 29, 2025, Inhibikase Therapeutics, Inc. (the “Company”) reported results from the Phase 2 201 trial (the “201 Trial”) evaluating risvodetinib, a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, in untreated Parkinson’s disease. • The 201 Trial enrolled 126 people with untreated Parkinson’s disease who were, on average, 14 months from diagnosis and were dosed in equal proportions at 50 mg, 100 mg, 200 mg or placebo for 12 weeks. The primary endpoints o…

Termination of a Material Definitive Agreement. On February 1, 2024, Inhibikase Therapeutics, Inc. (the “ Company ”) entered into an At the Market Offering Agreement (the “ ATM Agreement ”) with H.C. Wainwright & Co., LLC, as sales agent (the “ Agent ”), pursuant to which the Company may, from time to time, issue and sell shares of its common stock, in an aggregate offering price of up to $5,659,255, through or to the Agent. Under the terms of the ATM Agreement, the Agent may sell the shares…

Director — Dr. Paul Grint, Ms. Gisele Dion: The resignation of Dr. Grint and Ms. Dion was orderly, with their roles filled by new directors.

Entry into a Material Definitive Agreement. Closing of Private Placement Transaction As previously reported on its current report on Form 8-K filed with the Securities and Exchange Commission (“ Commision ”) on October 10, 2024 (the “ Prior 8-K ”), on October 9, 2024, Inhibikase Therapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) in connection with a private placement (the “ Private Placement ”) with certain institutional and other ac…

Unregistered Sales of Equity Securities. The information contained in

Director — Roberto Bellini, Amit Munshi, David Canner, Arvind Kush: The Board increased the number of directors and appointed four new directors to fill the vacancies.

Other Events. Settlement of Pivot Arbitration As previously disclosed, on April 26, 2024, the Company received a notice of a demand for arbitration with the American Arbitration Association from Pivot Holding LLC (“ Pivot ”), a successor in interest to Sphaera Pharma Pte. Ltd. (“ Sphaera ”), in connection with the Collaborative Research and Development Agreement dated February 29, 2012, as amended, between the Company and Sphaera (the “ Collaboration Agreement ”), alleging breach of contract…